Tirzepatide
For Research Use Only · Not for Human Consumption
Weight lossMetabolic
Tirzepatide is a synthetic 39-amino-acid peptide that activates both the GIP and GLP-1 incretin receptors. In preclinical and in-vitro models it is studied for receptor crosstalk, cAMP signalling, insulin-secretion kinetics and adipocyte metabolism. Supplied as lyophilized powder at ≥98% HPLC purity. For Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Potential benefits — preclinical research
- •Up to ~20.9% body-weight reduction at 72 weeks in the SURMOUNT-1 trial.
- •Dual GIP / GLP-1 receptor activation studied for superior glycaemic control vs single-agonist incretins.
- •Improved insulin sensitivity and post-prandial glucose excursions in T2D models.
- •Reduced visceral adipose tissue and hepatic fat in preclinical metabolic studies.
- •Lower systolic blood pressure and triglycerides reported as secondary endpoints in clinical trials.
Findings reported in published in-vitro / animal studies. Not therapeutic claims — for research use only.
Certificate of Analysis
View certificate—per vial